ZOLINZA: Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma

Sponsor

Samsung Medical Center (Other)

Overall Status

Terminated

CT.gov ID

NCT01578343

Collaborator

Seok Jin Kim (Other)

Enrollment

Location

Arm

Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Rationale In mantle cell lymphoma, the conventional chemotherapy achieves only temporary responses with a median duration of remissions only from 1 to 2 years. Therefore, mantle cell lymphoma is known as one of the B-cell lymphomas with poor prognosis. Although the treatment outcome of mantle cell lymphoma has been improved since intensive chemotherapy regimens such as HyperCVAD was used, a substantial number of patients are still frequently relapsed after chemotherapy. After relapse, most of them became refractory to various kinds of salvage treatment. That is why the results of most salvage chemotherapy regimens were disappointing. In addition, mantle cell lymphoma generally occurs in elderly people. Thus, intensive salvage chemotherapy may not be feasible for elderly patients. Therefore, an effective, novel combination treatment is urgently needed in relapsed or refractory mantle cell lymphoma patients.
Hypothesis

Vorinostat will produce synergism with a combination treatment regimen (Fludarabine, mitoxantrone, dexamethasone, FND) without overlapping toxicity
Vorinostat maintenance treatment will reduce the relapse rate in patients ineligible for autologous stem cell transplantation.

Purpose A phase II investigation to determin the effectiveness of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphomain patients with relapsed or refractory mantle cell lymphoma.

Condition or Disease	Intervention/Treatment	Phase
Mantle Cell Lymphoma	Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat	Phase 2

Detailed Description

Objectives 1.1 Primary objective • To determine the efficacy of vorinostat plus FND as an induction treatment

Response rate of vorinostat/FND 1.2 Secondary objective
Survival outcome
Overall survival and progression-free survival
To determine the efficacy of vorinostat maintenance treatment
Relapse rate • Toxicity of vorinostat/FND
Hematologic and non-hematologic toxicity

Study Design

Study Type:

Interventional

Actual Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Study Start Date :

Jun 1, 2012

Actual Primary Completion Date :

Sep 1, 2015

Actual Study Completion Date :

Feb 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Vorinostat-FND Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)	Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy) Consolidation treatment for responders Patients not eligible for transplantation Vorinostat maintenance up to 6 cycles 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle Delay of the start of the next cycle by up to 7 days will be acceptable. If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation High-dose chemotherapy followed by autologous stem cell transplantation Other Names: 1.Induction treatment (Total 4 cycles) D1-3 Fludarabine D1 Mitoxantrone D1-5 Dexamethasone Vorinostat D1-10 Vorinostat 2.Consolidation treatment for responders Patients not eligible for transplantation

Arm

Intervention/Treatment

Experimental: Vorinostat-FND

Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)

Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat

Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy) Consolidation treatment for responders Patients not eligible for transplantation Vorinostat maintenance up to 6 cycles 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle Delay of the start of the next cycle by up to 7 days will be acceptable. If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation High-dose chemotherapy followed by autologous stem cell transplantation

Other Names:

1.Induction treatment (Total 4 cycles) D1-3 Fludarabine D1 Mitoxantrone D1-5 Dexamethasone Vorinostat D1-10 Vorinostat

2.Consolidation treatment for responders Patients not eligible for transplantation

Outcome Measures

Primary Outcome Measures

To determine the efficacy of vorinostat plus FND as an induction treatment confirmed by CT or MRI (PET/CT as indicated) [A) After 8weeks and 16 weeks of the treatment]
B) Response criteria 1) Complete response (CR): Disappearance of all detectable clinical and radiographic evidence of disease 2) Partial response (PR): ≥50% decrease in sum of product diameter (SPD) of 6 nodes/nodal masses 3) Stable disease (SD): Disease status is less than PR, but is not PD 4) Progressive disease (PD): Appearance of any new lesions

Secondary Outcome Measures

To determine the efficacy of vorinostat maintenance treatment, survival outcome and toxicity of vorinostat/FND measured by CT or MRI scan, CTCAE ver 4.0 [every 3 months during the 1st two years after enrollment]
A) Disease status evaluation every 3 months during the 1st two years after enrollment B) Monitoring survival status during the five years after enrollment C) Toxicity evaluation

Eligibility Criteria

Criteria

Ages Eligible for Study:

19 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion

Histologically proven mantle cell lymphoma
Adequate organ function as defined by the following criteria:
Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy
Total serum bilirubin ≤1.5 x ULN
Absolute neutrophil count (ANC) ≥1500/µL
Platelets ≥100,000/µL
Hemoglobin ≥9.0 g/dL (may be transfused or erythropoietin treated)
Serum calcium ≤12.0 mg/dL
Serum creatinine ≤1.5 x ULN
Normal potassium and magnesium at baseline
All patients should be relapsed or refractory patients after previous treatments including chemotherapy .
At least one measurable lesion (lymph node or tumor mass)
The size of lesion must be > 1.0cm in the greatest transverse diameter
ECOG PS 0-2
Serum HCG test: negative if a patient is female eligible for pregnancy

Exclusion

Major surgery or radiation therapy within 4 weeks of starting the study treatment.
History of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease or secondary CNS involvement on CT or MRI scan.
Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.
Pregnancy or breastfeeding.
Patients with HIV positive
Patients with HBs antigen positive
Patients with anti-HCV positive
History of the use of another HDAC inhibitor: e.g. valproic acid